Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。